| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Nicholas B Norgard | Q46363825 |
| P2093 | author name string | James J Dinicolantonio | |
| Benjamin Wee | |||
| Taylor J Topping | |||
| P2860 | cites work | Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation | Q22305336 |
| Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks | Q24245569 | ||
| Drug interactions with warfarin: what clinicians need to know | Q24681312 | ||
| Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial | Q26248603 | ||
| Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? | Q28166299 | ||
| Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation | Q28201331 | ||
| Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial | Q28219363 | ||
| Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects | Q28247385 | ||
| Dabigatran versus warfarin in patients with atrial fibrillation | Q28256895 | ||
| Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity | Q28278166 | ||
| 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines | Q28305368 | ||
| Validation of Clinical Classification Schemes for Predicting Stroke | Q29028208 | ||
| Heart disease and stroke statistics--2011 update: a report from the American Heart Association | Q29547236 | ||
| Atrial fibrillation as an independent risk factor for stroke: the Framingham Study | Q29614200 | ||
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
| Apixaban versus warfarin in patients with atrial fibrillation | Q29617563 | ||
| Apixaban metabolism and pharmacokinetics after oral administration to humans | Q33373622 | ||
| Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects | Q33438731 | ||
| The role of tissue factor and factor VIIa in hemostasis | Q33728350 | ||
| Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial | Q34134664 | ||
| Apixaban in patients with atrial fibrillation | Q34163710 | ||
| Rising rates of hospital admissions for atrial fibrillation. | Q34271333 | ||
| Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor | Q34381344 | ||
| Systematic overview of warfarin and its drug and food interactions | Q34420870 | ||
| Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects | Q34549019 | ||
| Dietary vitamin K intake and anticoagulation in elderly patients | Q34586791 | ||
| Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate | Q34590281 | ||
| Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects | Q34605304 | ||
| Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers | Q34615829 | ||
| Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial | Q34624280 | ||
| Stroke severity in atrial fibrillation. The Framingham Study | Q34735226 | ||
| Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788530 | ||
| Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development | Q34900298 | ||
| Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor | Q34964874 | ||
| Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population | Q35583944 | ||
| Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis | Q35827856 | ||
| The safety of warfarin therapy in the nursing home setting. | Q36831383 | ||
| Drug and dietary interactions of the new and emerging oral anticoagulants | Q37768229 | ||
| Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence | Q40310174 | ||
| The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects | Q41121441 | ||
| Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial | Q42830264 | ||
| Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation | Q42839725 | ||
| Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study | Q43137255 | ||
| In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | Q43235385 | ||
| Can we rely on RE-LY? | Q43283546 | ||
| Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated | Q43502208 | ||
| Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients | Q43757356 | ||
| Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators | Q43764537 | ||
| Canadian atrial fibrillation anticoaguiation (CAFA) study | Q43928649 | ||
| Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy | Q43942672 | ||
| Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial | Q44054411 | ||
| The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation | Q44153210 | ||
| Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin | Q44724648 | ||
| National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation | Q44725124 | ||
| Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols | Q44879412 | ||
| Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia | Q45038588 | ||
| Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. | Q45982702 | ||
| The use of dabigatran immediately after atrial fibrillation ablation. | Q46007747 | ||
| Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans | Q46131621 | ||
| Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range | Q46173062 | ||
| Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects | Q46835939 | ||
| The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans | Q46897672 | ||
| Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). | Q46939643 | ||
| Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation | Q49811601 | ||
| Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. | Q50684421 | ||
| Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. | Q50697459 | ||
| An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. | Q51871528 | ||
| Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients. A prospective, controlled trial. | Q51984273 | ||
| Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. | Q52106400 | ||
| Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. | Q54114563 | ||
| Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation | Q56620375 | ||
| Dietary Vitamin K Variability Affects International Normalized Ratio (INR) Coagulation Indices | Q58401933 | ||
| Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke | Q60508097 | ||
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications | Q63241969 | ||
| Stroke Prevention in Atrial Fibrillation Study. Final results | Q67925848 | ||
| Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study | Q72671504 | ||
| Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose | Q77186548 | ||
| Early detection of patients with a poor response to vitamin K antagonists: the clinical impact of individual time within target range in patients with heart disease | Q79898774 | ||
| Dabigatran etexilate | Q81556407 | ||
| Newly identified events in the RE-LY trial | Q82292992 | ||
| Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin | Q82627288 | ||
| Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion | Q83104350 | ||
| The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement | Q83290003 | ||
| Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized controlled trial | Q84529411 | ||
| Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects | Q94705893 | ||
| P433 | issue | 3 | |
| P921 | main subject | anticoagulant | Q215118 |
| atrial fibrillation | Q815819 | ||
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 123-136 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Therapeutic advances in chronic disease | Q26842871 |
| P1476 | title | Novel anticoagulants in atrial fibrillation stroke prevention | |
| P478 | volume | 3 |
| Q37370565 | Clinical diseases with thrombotic risk and their pharmacologycal treatment: how they change the therapeutic attitude in dental treatments. |
| Q50702069 | Inhibitory Effect of Triterpenoids from Panax ginseng on Coagulation Factor X. |
| Q37641289 | New oral anticoagulants for atrial fibrillation: are they worth the risk? |
| Q38113554 | Oral anticoagulation therapy for elderly patients with atrial fibrillation: utility of bleeding risk covariates to better understand and moderate risks |
| Q38728028 | Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices? |
Search more.